Hematology

Journal Club ft. NEJM publications

Questions discussed in this category

When, if ever, would you select a three-drug regimen instead of four-drug regimen in patients with newly diagnosed Multiple Myeloma?

3 Answers available

What is your preferred first line treatment regimen for patients with untreated transplant-ineligible MM?

Triplet v. Quadruplet? What regimen? How would this change for a patient with high risk cytogenetics?

6 Answers available

What clinical or logistical factors influence your choice of anti-CD38 antibody in first line treatment of Multiple Myeloma?

For example, per the IMROZ trial methodology, Isatuximab dosing does not change to monthly dosing until >18 cycles which can impact patient QoL and...

3 Answers available

Are you still recommending autologous stem cell transplantation (ASCT) for all eligible myeloma patients who achieve remission after induction with a quadruplet regimen?

Or can we omit it in older patients given efficacy of these regimens? Is transplant-eligibility still an important distinction up front given options ...

2 Answers available

How does one approach maintenance treatment in transplant ineligible patients with newly diagnosed multiple myeloma?

Do the IMROZ and BENEFIT trials inform choice? In IMROZ, the high-risk population received only revlimid/dexamethasone maintenance. Should they have g...

2 Answers available

Does tolerance of prior BTKi therapy or specific agent used (e.g., ibrutinib, acalabrutinib) influence your starting dose of pirtobrutinib?

2 Answers available

How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?

2 Answers available

What post-protocol therapies did patients on the BRUIN trial in CLL receive, and how did these therapies impact outcomes?

3 Answers available

How do CLL patients with downstream treatment-resistant mutations such as PLCG2 respond to pirtobrutinib?

Are there other mutations/biomarkers in CLL which may specifically predict for response or resistance to pirtobrutinib?

4 Answers available

Papers discussed in this category

Lancet (London, England), 2017-02-04

Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.

British journal of haematology, 2018-07

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma.

The New England journal of medicine, 2019-05-30

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.

J Geriatr Oncol, 2021 Mar 06

Bortezomib in first-line therapy is associated with falls in older adults with multiple myeloma.

Leukemia, 2018 Apr 25

Patient-centered practice in elderly myeloma patients: an overview and consensus from the European Myeloma Network (EMN).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Sep 27

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma.

The New England journal of medicine, 2022 Feb 24

Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.

N Engl J Med, 2023 Jul 6

Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia.

Blood advances, 2023 Jun 27

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.

Blood advances, 2022 Oct 25

Enrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistance.

The Lancet. Oncology, 2018-01

Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.

The New England journal of medicine, 2018-03-22

Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Blood advances, 2024 Mar 26

Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.

Haematologica, 2024 Jun 01

Pirtobrutinib venetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison.

Lancet Oncol, 2021 Nov 11

Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.

The Lancet. Oncology, 2021 Oct 13

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.

The New England journal of medicine, 2024 Jun 03

Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Nature medicine, 2024 Jun 03

Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial.

The New England journal of medicine, 2017-04-06

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Blood,

Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.

N Engl J Med, 2022 Jun 05

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.

The New England journal of medicine, 2023 Dec 12

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Related Topics in Hematology